Adult patients with cystic fibrosis typically exhibit a mean therapy adherence of around 35% [1], resulting in suboptimal therapy outcomes. 
 
Consistent therapy adherence is particularly important in antibiotic therapy. We hypothesized that adherence could be improved if patients had more transparency about their therapy behavior both towards themselves and towards their caring physician which increases the self-efficacy experience of the patient.
 
An optimized [eFlow® Technology] nebulizer was used in a test market with a controller [eTrack Controller] (PARI Pharma, Germany) to deliver drugs to the lungs via inhalation as part of standard care and to objectively monitor adherence. The therapy plan and all inhalation data were available to the patients via the [PARI Connect] app on their mobile phone and to the accompanying physicians via a web portal. The app includes a therapy reminder and both the app and the web portal enable the evaluation and graphical representation of each patient's adherence.
 
In this test market we observed an average adherence of 52% in 70 patients who used the nebulizer together with the [PARI Connect] app over a total period of 2 years. Adherence was particularly high in the first three months of using the new device.

The evaluation shows that the use of the [PARI Connect] app in combination with the controller [eTrack Controller] can significantly improve patient adherence and that patients are open to use an app to support them.
Future motivational features may stabilize the increase in adherence we observed during the first three months.

[1] Wildman MJ, et al. Thorax 2021;0:1?10. doi:10.1136/thoraxjnl-2021-217594